MegaTrials (> 5,000 patients) - DCRI
CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy | Markets Insider
CSL to start Phase lll trial of CSL112 for heart attack survivors - Clinical Trials Arena
JCDD | Free Full-Text | Impact of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials | HTML
MemorialCare Heart and Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II) | DAIC
Elizabeth Medenilla Clinical Trials and Research Studies of New Treatments - University of Pennsylvania (UPenn)
MegaTrials (> 5,000 patients) - DCRI
Research & Innovation on Twitter: "PI Kelvin Lee and research nurse @clhyland_hewitt attending the AEGIS-II investigator meeting to prepare for study set up #aegis2trial @ULHT_News @Johnsonward3 @ULHTHeartCentre @susiebutler20 @NIHRCRNEastMids https ...
Apostolos Dimos MD, MSc - AEGIS-II Trial (NCT03473223) Sub-Investigator - General University Hospital of Larissa | LinkedIn
AEGIS II | Valley Health System
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? - Annals of Oncology
![figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram](https://www.researchgate.net/publication/346206981/figure/fig2/AS:961661917741057@1606289476103/figures-fig1Study-design-and-timelineFMC-first-medical-contact.jpg "figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram")
figures_fig1]Study design and timeline.FMC, first medical contact. | Download Scientific Diagram
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH ...
CSL Behring on Twitter: "Today, the study design for our landmark Phase 3 AEGIS-II trial was published in @AmericanHeartJ Read more about our cardiovascular research program involving #heartattack survivors: https://t.co/WByn9r3ny6 @CMichaelGibson ...
2019 Annual Report: Reducing Risk, Changing Paradigms - DCRI
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction | Circulation
Update on HDL Infusions and Atherosclerosis Regression in
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome | JACC: Heart Failure
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel | Journal of the American College of Cardiology
AEGIS II Design AHA
MemorialCare Heart & Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II)
CSL Confirms Phase 3 Clinical Trial of New Therapy for Heart Attack Survivors
PDF) Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo- controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial - The Lancet Diabetes & Endocrinology
